Tyra Biosciences, Inc.
TYRAUnited States
20 filed reports · 263 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
20 reports · Sep 2021 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 15 | 2,126 | Sep 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 1,542 | Dec 2021 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 272 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 13, 2026 | 172 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 2, 2026 | 429 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 191 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 14, 2025 | 130 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 138 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 27, 2025 | 291 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 141 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 121 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 145 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 19, 2024 | 284 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 122 | Open |
Financial data
263 concepts · 3,668 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial263 concepts · 3,668 facts · Mar 2020 to Jul 2026
- US Treasury Securities51 · Dec 2023 to Jun 2026
- Accrued other general and administrative fees39 · Dec 2020 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value32 · Mar 2020 to Jun 2026
- Net income loss32 · Mar 2020 to Jun 2026
- Stockholders equity (US GAAP)32 · Mar 2020 to Jun 2026
- Cash and cash equivalents at carrying value30 · Sep 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents30 · Sep 2020 to Jun 2026
- General and administrative expense (US GAAP)30 · Sep 2020 to Jun 2026
- Nonoperating income expense30 · Sep 2020 to Jun 2026
- Operating expenses (US GAAP)30 · Sep 2020 to Jun 2026
- Operating income loss30 · Sep 2020 to Jun 2026
- Operating lease cost30 · Sep 2020 to Jun 2026
- Research and development expense30 · Sep 2020 to Jun 2026
- Capital expenditures incurred but not yet paid29 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect29 · Dec 2020 to Jun 2026
- Depreciation depletion and amortization29 · Dec 2020 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities29 · Dec 2020 to Jun 2026
- Increase decrease in prepaid expenses other29 · Dec 2020 to Jun 2026
- Net cash provided by used in financing activities29 · Dec 2020 to Jun 2026
- Net cash provided by used in investing activities29 · Dec 2020 to Jun 2026
- Net cash provided by used in operating activities29 · Dec 2020 to Jun 2026
- Payments to acquire property plant and equipment29 · Dec 2020 to Jun 2026
- Right-of-use assets and lease liabilities, net29 · Dec 2020 to Jun 2026
- Share based compensation29 · Dec 2020 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.